The effect of astaxanthin supplementation on inflammatory markers, oxidative stress indices, lipid profile, uric acid level, blood pressure, endothelial function, quality of life and disease symptoms in heart failure subjects.

Start Date21 Jul 2024

Sponsor / Collaborator

Isfahan University of Medical Sciences

IRCT20231028059882N2 / RecruitingPhase 3IIT

Effect of Astaxanthin on Advanced Glycation End Products (AGE)-Receptor for AGE (RAGE)-Inflammation Signaling pathway in Women with Polycystic Ovarian Syndrome-Associated Infertility

Start Date21 Jun 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

NCT06429059 / Enrolling by invitationPhase 2IIT

ROAR-DIGAP: A Widely Inclusive, Largely Virtual Pilot Trial Utilizing DIGAP (Deep Integrated Genomics Analysis Platform) To Personalize Treatments

GenieUs developed an analysis platform that will be tested to separate study participants with ALS into four categories based on blood work. These general categories are neuroinflammation, oxidative stress, impaired autophagy & axonal transport, and mitochondrial dysfunction. Once a disease category is established, participants in this study will receive one of four individualized supplements for 6 months and we will determine whether these are slowing ALS progression: Astaxanthin will be given for the category of neuroinflammation, Protandim for oxidative stress, Melatonin for impaired autophagy and MitoQ for mitochondrial dysfunction. During the first 3 months, participants will have routine monitoring and in months 3 through 9 they will receive the assigned supplement.

Start Date12 Jun 2024

Sponsor / Collaborator

Duke University

[+1]

100 Clinical Results associated with Astaxanthin

100 Translational Medicine associated with Astaxanthin

100 Patents (Medical) associated with Astaxanthin

3,381

Literatures (Medical) associated with Astaxanthin

01 Jan 2025·FOOD CHEMISTRY

Preparation and characterization of astaxanthin-loaded liposomes by phytosterol oleate instead of cholesterol

Article

Author: Liu, Mei ; Diao, Jing ; Wang, Ying ; Liu, Tianhong ; Zhong, Chen ; Li, Xueting

Hydrophobic bioactive compounds like astaxanthin (AST) exhibit poor water solubility and low bioavailability. Liposomes, which serve as nanocarriers, are known for their excellent biocompatibility and minimal immunogenicity. Traditionally, liposomes have been primarily constructed using phospholipids and cholesterol. However, the intake of cholesterol may pose a risk to human health. Phytosterol ester was reported to reduce level of cholesterol and improve properties of liposomes. In this study, phytosterol oleate was used to prepare liposomes instead of cholesterol to deliver AST (AST-P-Lip). The size range of AST-P-Lip was 100-220 nm, and the morphology was complete and uniform. In vitro studies showed that AST-P-Lip significantly enhanced the antioxidant activity and oral bioavailability of AST. During simulated digestion, AST-P-Lip protected AST from damage by gastric and intestinal digestive fluid. Additionally, AST-P-Lip had a good storage stability and safety. These results provide references for the preparation of novel liposomes and the delivery of bioactive compounds.

01 Jan 2025·FOOD CHEMISTRY

Preparation of cellulose-based nanoparticles via electrostatic self-assembly for the pH-responsive delivery of astaxanthin

Article

Author: Cao, Ailing ; Li, Jian ; Gan, Miaoyu ; Cai, Luyun ; Luan, Qian ; Xiang, Xia

Oral administration of astaxanthin (AST), a potent antioxidant, is limited owing to its low solubility, physicochemical stability, and bioavailability. This study developed pH-responsive nanocarriers by the electrostatic self-assembly of 2,2,6,6-tetramethylpiperidine-1-oxyradical (TEMPO)-oxidized cellulose nanofibers (TCNFs) and chitosan (CS) to enhance the intestinal delivery of AST. The TCNF/CS@AST nanoparticles were optimized through single-factor experiments and Box-Behnken design, subsequently overcoming the hydrophobicity of AST and demonstrating improved stability against environmental stressors and controlled release in the intestinal environment. Transmission electron microscopy confirmed the near-spherical shape of these nanoparticles, with an average hydrodynamic diameter of 64 nm. TCNF/CS@AST enhanced the antioxidant effectiveness of AST after digestion and in lipopolysaccharide-stimulated RAW 264.7 cells while demonstrating good cellular compatibility. These nanoparticles present a promising strategy for the oral delivery of hydrophobic bioactive compounds orally, with potential applications in precision nutrition.

01 Jan 2025·FOOD CHEMISTRY

Advance toward function, production, and delivery of natural astaxanthin: A promising candidate for food ingredients with future perspectives

Review

Author: Wang, Yuhua ; Yuan, Gaofeng ; Chen, Xiaoe ; Luo, Lu ; Zhang, Ying ; Han, Tiantian ; Zhang, Jing ; Liu, Meizhen ; Fang, Xubo ; Han, Fangrui

Astaxanthin (AST) exhibits potent antioxidant activity, effectively preventing neurological diseases and cancer. Presently, producing AST from microorganisms like Haematococcus pluvialis and Phaffia rhodozyma is a growing trend. This review summarizes the main research topics on AST in the past five years. AST plays a crucial role in cancer and diabetes prevention, as well as neuroprotection, however, the presence of both free and esterified forms of AST results in differences in their functionality and applications. The primary challenges in industrial production of natural AST lie in breeding high-yield natural producers and developing methods to enhance yield. The use of high-quality food matrix materials and preparation methods is crucial for the delivery system of loaded AST. This study elucidates the bottlenecks and future development directions encountered by natural AST during industrialization, aiming to promote the healthy and rapid growth of the food industry.

News (Medical) associated with Astaxanthin

02 Apr 2024

·www.globenewswire.com

Pressure BioSciences’ Uncle Bud’s Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection”

PBIO Receives Critical Processor License for Industrial Hemp in MA.New License and Relocation to Enhanced Manufacturing Facility Allows Company to Supplement Production with West Coast Partner to Manage Anticipated Onset of Purchase Order Increases. CANTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBIO” or the “Company”), a leading innovator in high-pressure nanotechnology and a pioneer in the development of novel, broadly-enabling, pressure-based instruments and nanoemulsion products and services for the health & wellness, food & beverage, nutraceutical, cosmeceutical, and other industries, today announced that its wholly-owned Uncle Bud’s Health & Wellness consumer packaged goods subsidiary (“Uncle Bud’s”) has experienced significant sales activity in its revolutionary nanoemulsified CBD product offered in the initial launch of its highly touted “Premium Collection” of UltraShear™ processed nanoemulsion products. Click here for more info on Uncle Bud's Premium Collection. In an exciting move for natural wellness enthusiasts, Uncle Bud’s recently launched its UltraShear-processed “Premium Collection” of state-of-the-art nanoemulsified products, representing the pinnacle of innovation, quality, and commitment to clean and all-natural wellness solutions. The Premium Collection was an immediate success, highlighted by the unprecedented response to its initial product in the Collection - the CBD Body Revive Spray with 1200mg of Nano-CBD. PBIO’s multi-patented Ultra Shear Technology™ (UltraShear™ or UST™) platform allows oil-soluble active molecules (e.g., vitamin D3, retinol, CBD) to be prepared into high quality nanoemulsions that ensure rapid absorption and unparalleled bioavailability of the oil-based active ingredients into the water-based biochemistry of humans, animals, and plants. A recently published scientific study in a peer-reviewed journal by world-renowned researchers confirmed PBIO’s UltraShear nanoemulsion platform vastly outperformed other delivery systems with unmatched speed, efficiency, and bioavailability. UltraShear Bioavailability Study 2023. “Uncle Bud’s newly launched Nano-CBD Body Revive Spray, an innovative, all plant-based, organic, highly bioavailable flagship product processed using PBIO’s UltraShear platform, captured an impressive 30% conversion of Uncle Bud’s total CBD Revive Spray product revenue in March alone,” commented John Hollister, PBIO’s Director of Sales and Marketing. “The surge in demand for this revolutionary new product prompted an urgent restocking of this initial product in Uncle Bud’s Premium Collection, in order to meet the enthusiastic consumer response to date!” In a separate, critically important accomplishment, PBIO announced it had received its Massachusetts processing license for industrial hemp (No. 25240244P). The license was granted by the MA Department of Agricultural Resources (“MDAR”), the hemp processing licensing entity under federal and state law in the Commonwealth of MA. This achievement enables PBIO to develop, manufacture, market, and sell UST-processed products into the rapidly expanding CBD marketplace. Ken Micciche, PBIO’s Director of Business Development, added: “With our relocation into a larger and significantly enhanced manufacturing facility, with our new MDAR processor license, and with an accelerated focus on the generation of major revenue from sales of our unique nanoemulsified products, we are now prepared for the expected onset of orders for existing (e.g., CBD, Astaxanthin) and new (e.g., Acai, Retinol) UltraShear-processed nanoemulsified products.” About Uncle Bud’s Health and WellnessLaunched in 2018 with a trailblazing hemp-based Pain Relief product, Uncle Bud’s has rapidly captured an innovative leadership role in the Hemp Seed Oil, Cannabidiol (CBD), and the broader Health & Wellness industry. The Uncle Bud’s brand is revered for its unwavering commitment to domestic manufacturing excellence, setting benchmarks for its organic, preservative-free, non-GMO standards and its ethical cruelty-free practices. Uncle Bud’s is dedicated to the highest-quality formulations and to continuous improvement, guided by the latest scientific research and development innovations – including the revolutionary performance breakthroughs delivered by PBIO’s patented UltraShear™ processing platform. Uncle Bud’s diverse product portfolio addresses an ever-broadening spectrum of consumer needs, encompassing pain relief, sophisticated skincare solutions, personal wellness and athletic recovery products, and specialized pet care items. Learn More: www.unclebudshemp.com * Follow Us On Social Media: @UncleBuds_Hemp. About Pressure BioSciences, Inc.Pressure BioSciences, Inc. (OTCQB: PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our patented, scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform allows for the creation of stable nanoemulsions of otherwise immiscible oil-based active components in water. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our patented original enabling platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. Our patented BaroFold™ technology platform positions us to provide valuable contract services and GMP manufacturing equipment to the bio-pharmaceuticals industry. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers. Forward Looking StatementsThis press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied, or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. In evaluating these statements, you should specifically consider various factors. Actual events or results may differ materially. These and other factors may cause our actual results to differ materially from any forward-looking statement. These risks, uncertainties, and other factors include, but are not limited to, the risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law. For more information about PBIO, Uncle Bud’s, and this press release, please click on the following website links:http://www.pressurebiosciences.com www.unclebudshemp.com Please visit us on Facebook, LinkedIn, and Twitter. CBD Body Revive SprayAll Natural, Fast Acting, Plant Based, Preservative Free, Best-in-Class,UltraShear-processed Nano CBD…the first in a series of groundbreaking premium nanoemulsified products designed to meet the needs of consumers looking for the highest quality and performance in natural and effective wellness solutions.Click here for more info on Uncle Bud's Premium Collection. Press Contacts: Richard T. Schumacher, President & CEOJohn B. Hollister, Director of Sales and MarketingKenneth F. Micciche, Director of Business Development (508) 230-1828 (T)(805) 908-5719 (T)(508) 230-1828 (T) A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6a5bec8b-25e8-44cb-83de-1368fd142375

License out/in

13 Mar 2024

·www.prnewswire.com

KAS Announces $3M Funding Round to Expand Production of its Natural Algae Astaxanthin

Company's innovative approach enables high-quality natural algae astaxanthin production at faster and more affordable rates New funding will support company plans to reach commercialization this year HONOLULU, March 13, 2024 /PRNewswire/ -- Kuehnle AgroSystems ("KAS"), a leading microalgal innovation and production company, today announced that it has raised a $3 million Series A2 funding round led by S2G Ventures. The funding will accelerate the commercialization of KAS's pioneering method for producing natural astaxanthin from microalgae, a key component in sustainable aquaculture systems as well as a clinically proven human nutraceutical. KAS has patented an innovative process that uses dark fermentation in closed vertical tank systems to produce high-quality natural algae astaxanthin. Utilizing a more sustainable feedstock and production method than current natural and synthetic astaxanthin production methods, KAS's process results in lower production costs, higher yields, faster growth times, and less water and energy consumption. Astaxanthin is a carotenoid with antioxidant properties present in natural aquatic algae, which is consumed by salmonids and shrimp and gives these species their characteristic red color. In aquaculture systems, which produce over 50% of the seafood we eat globally, astaxanthin is incorporated to provide similar pigments. However, 95% of astaxanthin currently used in aquaculture feed is synthetic and derived from petrochemicals. KAS aims to replace synthetic with natural algal astaxanthin, addressing a market that is estimated to be valued at around $3.7 billion. "Strong consumer preference for natural inputs is expected to accelerate the transition from synthetic to natural astaxanthin," said Claude Kaplan, chief executive officer of KAS. "With our ability to generate greater astaxanthin output volumes, quicker and at a reduced cost compared to light-dependent methods, this funding strongly positions KAS to respond to the rapidly expanding needs of the market." "KAS's fermentation breakthrough, natural strain development process, and sustainable production method all have the potential to transform the natural astaxanthin market, a key input for more sustainable aquaculture practices that can drive better outcomes for people and the planet," said Larsen Mettler, Managing Director at S2G Ventures. "We are proud to be part of KAS's journey and look forward to supporting the impact they are poised to make in the market." Existing backers of KAS include Aqua-Spark, Hatch and Cavallo Ventures. "We continue to be impressed by the KAS team's capacity to leverage their scientific and commercial knowledge to produce a truly innovative solution for replacing synthetic with natural astaxanthin," said Lissy Smit, CEO at Aqua-Spark. "As the aquaculture industry continues to grow at a rapid pace, we need more companies like KAS that are solving core challenges in the value chain to ensure our food system is healthier and more sustainable for consumers and the planet." KAS will initially launch with its European-based production partner with the capacity to distribute globally. This new funding will enable KAS to exploit its ability to use standard fermentation equipment, to swiftly expand production through leveraging contract manufacturers, with the option to bring production in-house in the future. And while KAS' process is inherently more resource efficient than competitors, the company's technology also holds future potential for recycling the gas generated during fermentation to produce feedstock to be fed back into the fermentation process creating fully circular algal products. About KAS: Kuehnle AgroSystems, Inc. (KAS), founded in 2007, is a Hawaii-based microalgae development company with a world-class team of professionals. KAS uses its extensive library of Hawaiian microalgal strains to research, develop and produce specialty chemicals and raw materials to make life better. Our customers include multinational corporations along with valued regional companies and brands that require sustainable plant-based ingredients for animal feeds, human health, food, and personal care. Industrial fermentation allows our ingredients to be cultured at lower cost with highest efficiency and quality, and enables rapid access to markets by ourselves and our partners. Learn more at kuehnleagro.com. About S2G Ventures: S2G Ventures partners with entrepreneurs who are working on solutions to some of the world's greatest challenges across the food, agriculture, oceans, and energy markets. The firm provides capital, mentorship, and value-added resources to companies pursuing innovative market-based solutions that generate positive social, environmental, and financial returns. S2G structures flexible capital solutions that can range from seed and venture funding through growth equity to debt and infrastructure financing. For more information about S2G, visit s2gventures.com or connect with us on LinkedIn. Media Contact: Chelsea Hokenson [email protected] SOURCE Kuehnle AgroSystems

26 Sep 2023

·www.biospace.com

Prodec Global Launches CORE ASX® by HEBE LIFE to Support Healthy and Active Lifestyle

Revolutionary New Supplement Takes Comprehensive Approach to Longevity and Performance [WILMSLOW, 19 SEPTEMBER 2023] - Prodec Global UK Ltd unveils today CORE ASX®, a new supplement designed to support human wellbeing and optimize athletic performance like never before. Developed by leaders in natural health, HEBE LIFE®, this product represents a milestone in supporting wellness from within and is an innovative daily supplement, combining cutting-edge science with nature's most powerful antioxidant molecule. At the core of this formula is patent natural Astaxanthin (ASX), a powerful antioxidant found abundantly in microalgae. Often called "The King of Antioxidants”, ASX harnesses the immense benefits of natural Astaxanthin to support cellular health, immunity, beauty, and active lifestyles. Extensive research has revealed Astaxanthin’s immense ability to fight oxidative stress on a cellular level, but CORE ASX® takes this protection to an entirely new dimension. With the addition of Vitamin E and C, this supplement arms the body with next-level defenses against aging. CORE ASX® active ingredient is backed with more than 300 clinical trials in different fields of skin health, diabetes, cardiovascular diseases, and sarcopenia, and intervenes at a mitochondrial level. Natural ASX’s unique antioxidant molecules counteract the effects of oxidative stress by supporting muscle performance, endurance and recovery, allowing athletes to workout harder and recuperate faster. CORE ASX® is Informed Sport certified, supporting muscle performance in athletes of all levels from amateurs to professionals, with complete peace of mind. Beyond the enhanced athletic performance, CORE ASX®, also strengthens the aging body from within. Its robust antioxidant support bolsters the traditionally weakening of our natural immunity as we get older, helping fight inflammation and infection. CORE ASX®, even helps counters visible signs of aging by hydrating skin from the dermis up for a more youthful glow. Retinal circulation is improved to reduce eye fatigue. With its comprehensive, multi-benefit formula, CORE ASX® represents the next generation of supplements for supporting health, wellness and active lifestyle. "At The Prodec Collection, our highest purpose is empowering communities to live life to its fullest through innovative solutions rooted in science,” said Hélène Raad, Managing Director, Prodec Global UK Ltd. “CORE ASX® represents the culmination of years of intensive research and clinical validations to develop a product capable of truly extending human prime. I’m incredibly proud that we can offer such a groundbreaking formula accessible to all.” CORE ASX® by HEBE LIFE® capsules are vegetarian-friendly, non-GMO, Kosher and Halal certified. It includes added vitamins C and E to further augment its effects. CORE ASX® is now available directly from The Prodec Collection: for $369. - ENDS - Notes to Editor For more information or to arrange an interview, please contact tpc@hopscotch.com. About Prodec Global UK Ltd. Prodec Global UK Ltd believes in empowering individuals to live their best lives by offering high-quality health and wellness products that promote well-being and vitality. Prodec Global curates and delivers a selection of high-quality health and wellness products to meet consumers’ diverse needs. With thorough research and scrutiny, Prodec Global selects ingredients and formulas that meet real needs and offer real solutions. By focusing on the best in quality, excellence and results, Prodec Global brings affordable luxury to the everyday consumer. Products available in the U.S. include GPH 5 Complex® and CORE ASX®. Learn more at and join the movement to optimize wellness from within by following Prodec Global UK Ltd on LinkedIn.

100 Deals associated with Astaxanthin

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	V06D	DB06543

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Nutrition Disorders	-	Cyanotech Corp.	01 Jan 1999

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertriglyceridemia	Preclinical	US	Cardax Pharmaceuticals, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ARVO2008	Not Applicable	Choroidal Neovascularization	-	AST treatment	yrdfbpjfzb(rhxocgmrzt) = kmyawoyqdp fsmwgqtxkz (nntbnvzvyi )	-	01 May 2008
ARVO2004	Not Applicable	Age Related Macular Degeneration	50	astaxanthin	yoqocwlpwq(ihucbwtvay) = uuqygfwpqd hbeaajagqr (ritzfbpndh )	-	01 May 2004

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis